|
1.4 BIOLOGIE - TECHNOS, MODÈLES
|
|
|
|
2. ETIOLOGIE
|
|
|
|
2.11 ETIOLOGIE - ALIMENTATION
|
|
|
|
2.13 ETIOLOGIE - NDMA
|
|
|
EMA Lays Out Plans for Testing for Nitrosamine Impurities [RAPS]
|
|
|
|
|
|
By 26 April 2020, EMA is calling on companies to conduct a risk evaluation to identify products at risk of N-nitrosamine formation or (cross-)contamination and report the outcome and fill out either the template indicating “no risk identified” or “risk identified.”
|
|
|
|
|
|
|
3.1.1 PRÉVENTION - TABAC - E-CIGS
|
|
|
Characteristics of Patients in a National Outbreak of E-cigarette, or Vaping, Product Use–Associated Lung Injuries — United States, October 2019 [CDC]
|
|
|
|
|
|
As of October 22, 2019, a total of 1,604 cases of EVALI, including 34 deaths, were reported to CDC. Based on data collected as of October 15, 2019, use of tetrahydrocannabinol (THC)-containing products in the 3 months preceding symptom onset was reported by 86% of patients.
|
|
|
|
|
|
|
Deaths linked to vaping often involved THC products, not nicotine, CDC says [CNN]
|
|
|
|
|
|
"The data do continue to point towards THC-containing products," Dr. Anne Schuchat, CDC's principal deputy director, told reporters Friday. "But I'd like to stress that we don't know what the risky material or substance is. THC may be a marker for a way that cartridges were prepared or way that the devices are producing harm."
|
|
|
|
|
|
|
4.2 DÉP., DIAG. & PRONO. - GÉNOME
|
|
|
|
5.1 TRAITEMENTS - PRÉ-CLINIQUE
|
|
|
|
|
5.10 TRAITEMENTS - ESSAIS
|
|
|
|
5.12.11 IMMUNOTHÉRAPIES - PRÉ-CLINIQUE
|
|
|
|
5.12.3 IMMUNOTHÉRAPIES-COMBINAISONS
|
|
|
|
|
|
|
|
5.2 PHARMA
|
|
|
|
5.2.3 PHARMA - ÉCONOMIE
|
|
|
|
5.9 AACR
|
|
|
|
|
|
|
5.9.8 AACR - BIOTECH
|
|
|
|
Mirati clears first clinical hurdle in KRAS race against Amgen [Fierce Biotech]
|
|
|
|
|
|
As of the cutoff, 12 patients treated with MRTX849 had undergone a radiographic scan to assess the impact of the drug. Of the six non-small cell lung cancer (NSCLC) patients, three had partial responses, resulting in a response rate in line with that achieved by Amgen in the indication. One of the four colorectal cancer (CRC) patients assessed to date had a partial response.
|
|
|
|
|
|
|
|
|
|
|
6. LUTTE CONTRE LES CANCERS
|
|
|
|
6.6 PUBLICATIONS
|
|
|
|
6.7 DMP, BIG DATA & APPLIS
|
|
|
|
6.8 COMMUNICATION
|
|
|